Nunzia Pharmaceutical Corporation
OOTC:NUNZ0.00
USD
0.00
(0.00%)
ISIN
US67097W1027
CUSIP
67097W102
Return %
Stock
S&P 500
1Y
9,900.00
14.39
3Y
-96.67
81.42
5Y
-99.99
68.62
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Sara P. Gonzales
- Full Time Employees
- 4
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 1627 West 14th Street Long Beach CA United States 90813
- IPO Date
- Jan 23, 1995
- Website
- nunziapharma.com
- Similar Companies
- Business
- Nunzia Pharmaceutical Company Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company focused on developing and distributing therapies for behavioral symptoms associated with autism spectrum disorders, fragile X syndrome, ADHD, PTSD, and related anxiety-based conditions. The company manufactures, markets, and distributes its flagship product Nunzia, a nutraceutical supplement comprising a blend of 16 vitamins, minerals, and herbs including adaptogenic ingredients such as Rhodiola Rosea Root and Ashwagandha Root that target the hippocampus region of the brain to enhance sensory, social, and daily living skills; improve attention span, memory retention, focus, comprehension, and learning; and reduce anxiety, stress, fixations, fidgeting, and distractions, with products segmented into formulations for adults, kids, and teens offered through wholesalers and its website nunziapharma.com. Founded in 1986 and headquartered in Long Beach, California, the company changed its name from Arizona Gold and Onyx Mining Company in February 2018 to reflect its pivot to the healthcare sector serving patients and healthcare professionals primarily in the United States. No major acquisitions, partnerships, funding rounds, new product launches, or strategic expansions have been reported in the last one to two years.